1.
Cosentino, Francesco ✉ ; Grant, Peter J ; Aboyans, Victor ; Bailey, Clifford J ; Ceriello, Antonio ; Delgado, Victoria ; Federici, Massimo ; Filippatos, Gerasimos ; Grobbee, Diederick E ; Hansen, Tina Birgitte et al.
EUROPEAN HEART JOURNAL 41 : 2 pp. 255-323. , 69 p. (2020)
Közlemény:30804305 Egyeztetett Forrás Idéző Folyóiratcikk (Sokszerzős vagy csoportos szerzőségű szakcikk ) Nyilvános idézők összesen: 261 Független: 203 Függő: 58 Idézett közlemények száma: 6
Folyóiratcikk/Sokszerzős vagy csoportos szerzőségű szakcikk (Folyóiratcikk)/Tudományos[30804305] [Érvényesített]
Független idéző: 203, Függő idéző: 58, Nem vizsgált idéző: 0, Összes idéző: 261
  1. Dörr R. et al. 2019 ESC guidelines: consensus in Europe for 25 years. (2019) HERZ 0340-9937 1615-6692 44 8 674-675
  2. Ray Kausik K. et al. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. (2019) CARDIOVASCULAR DIABETOLOGY 1475-2840 18 1
  3. * Rocca Bianca et al. Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_SUPPL 92-105
  4. Bain S. C. et al. An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabet Med 2019; 36: 1063-1071. (2019) DIABETIC MEDICINE 0742-3071 1464-5491
  5. * Gelbenegger Georg et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. (2019) BMC MEDICINE 1741-7015 17 1
  6. Al-Sofiani Mohammed E. et al. Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence. (2019) CURRENT DIABETES REPORTS 1534-4827 1539-0829 19 10
  7. Karásek D.. Atherosclerosis in patients with type 1 diabetes. (2019) VNITRNI LEKARSTVI 0042-773X 1801-7592 65 12 775-782
  8. Chang L.-S. et al. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. (2019) CURRENT DIABETES REPORTS 1534-4827 1539-0829 19 12
  9. * Aboyans Victor et al. Cardio-diabetology: The new 'sweetheart' in cardiovascular prevention Introduction. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_SUPPL 5-6
  10. * van Dijk Wouter et al. Cardiovascular guidelines based on high-quality evidence: Are we getting there?. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 18 1915-1917
  11. Avgerinos I. et al. Cardiovascular risk reduction in type 2 diabetes: Therapeutic potential of dapagliflozin. (2019) DIABETES METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY 1178-7007 12 2549-2557
  12. Luescher Thomas F.. Chronic coronary syndromes: genetics, shear stress, and biomarkers. (2019) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 40 41 3367-3371
  13. [Anonymous]. Combination of Xarelto (R) (Rivaroxaban) 2.5 mg Twice Daily and Acetylsalicylic Acid is Now Recommended for the Treatment of Patients with Chronic Coronary Heart Disease. (2019) RATIONAL PHARMACOTHERAPY IN CARDIOLOGY / RATSIONAL'NAYA FARMAKOTERAPIYA V KARDIOLOGII 1819-6446 15 6 930-930
  14. Raschi Emanuel et al. Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. (2019) DRUG SAFETY 0114-5916 42 12 1409-1422
  15. * Fisher M.. Dapagliflozin and DAPA-HF: from glycaemic control to heart failure therapy. (2019) PRACTICAL DIABETES 2047-2897 2047-2900 1357-8170 36 6 192-193
  16. Shestakova M.V.. DECLARE-TIMI 58 trial in the context of EmpA-Reg outcomE and CANVAS. (2019) DIABETES MELLITUS 2072-0351 2072-0378 22 6 592-601
  17. * Schuett Katharina et al. Diabetes mellitus and heart. (2019) DIABETOLOGIE UND STOFFWECHSEL 1861-9002 14 S232-S234
  18. * Schuett Katharina et al. Diabetes Mellitus and the Heart. (2019) EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES 0947-7349 1439-3646 127 S102-S104
  19. * Schütt K. et al. Diabetes mellitus und Herz. (2019) DIABETOLOGIE UND STOFFWECHSEL 1861-9002 14 S232-S234
  20. Patel Hiren et al. Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis. (2019) DIABETES THERAPY 1869-6953 10 6 2321-2330
  21. Doerr R. et al. ESC-Guidelines 2019: Consensus in Europe for 25 Years. (2019) HERZ 0340-9937 1615-6692 44 8 674-675
  22. Zylka-Menhorn V.. European Congress of Cardiologists: Coronary heart disease is "anything but stable". (2019) DEUTSCHES ARZTEBLATT INTERNATIONAL 1866-0452 116 38 A1656-A1658
  23. * Prattichizzo F. et al. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_suppl 73-80
  24. * Ferrini Marc et al. Heart failure and its complications in patients with diabetes: Mounting evidence for a growing burden. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_SUPPL 106-113
  25. Abdellatif Mahmoud et al. Highlights of ESC Congress 2019: a report from the ESC Scientists of Tomorrow. (2019) CARDIOVASCULAR RESEARCH 0008-6363 1755-3245 115 13 E151-E154
  26. May Marcus et al. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology. (2019) THERAPEUTIC ADVENCES IN ENDOCRYNOLOGY AND METABOLISM 2042-0188 2042-0196 10
  27. Canivell Silvia et al. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. (2019) JOURNAL OF DIABETES RESEARCH 2314-6745 2314-6753 2019
  28. Liberale Luca et al. IL-1 beta and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. (2019) JOURNAL OF CLINICAL MEDICINE 2077-0383 8 11
  29. Nijpels Giel et al. Innovations in personalised diabetes care and risk management. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_SUPPL 125-132
  30. Rhainds D. et al. Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. (2019) EXPERT OPINION ON INVESTIGATIONAL DRUGS 1354-3784 28 12 1059-1079
  31. Katsiki N. et al. Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. (2019) ARCHIVES OF MEDICAL SCIENCE 1734-1922 1896-9151 15 6 1357-1364
  32. Hermans Michel P. et al. Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines. (2019) ACTA CARDIOLOGICA 0001-5385
  33. * Sillars Anne et al. Management of Lipid Abnormalities in Patients with Diabetes. (2019) CURRENT CARDIOLOGY REPORTS 1523-3782 1534-3170 21 11
  34. * Hansen D. et al. Management of patients with type 2 diabetes in cardiovascular rehabilitation. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_suppl 133-144
  35. Herdegen T.. Metformin. (2019) DEUTSCHE APOTHEKER-ZEITUNG 0011-9857 159 49
  36. * Marx N.. New ESC guidelines 2019 "Diabetes, prediabetes and cardiovascular diseases" Paradigm shift in reduction of cardiovascular risk in patients with diabetes mellitus. (2019) HERZ 0340-9937 1615-6692 44 8 684-687
  37. Luscher Thomas F.. Novel insights into body fat distribution and cardiometabolic risk. (2019) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 40 34 2833-2836
  38. Pharmacotherapy of type 1 diabetes. (2019) DEUTSCHE APOTHEKER-ZEITUNG 0011-9857 159 40
  39. Jaeckel E. et al. Pre-Existing Conditions Determining Current Diabetes Therapy: Mitigating Complications Involving the Heart and Kidneys. (2019) DIABETES STOFFWECHSEL UND HERZ 1861-7603 28 6 339-348
  40. Nincevic Vjera et al. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. (2019) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 20 23
  41. * Ryden Lars et al. Risk factor reduction in type 2 diabetes demands a multifactorial approach. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_SUPPL 81-91
  42. Arrarte V. et al. Selection of the best of 2019 in vascular risk and cardiac rehabilitation. (2019) REC: CardioClinics 2605-1532 2019 p. Article in press
  43. Petrie Mark C.. Sodium Glucose Cotransporter 2 Inhibitors Searching for Mechanisms in the Wake of Large, Positive Cardiovascular Outcomes Trials. (2019) CIRCULATION 0009-7322 1524-4539 140 21 1703-1705
  44. Dedov I et al. STANDARDS OF SPECIALIZED DIABETES CARE. (2019) DIABETES MELLITUS 2072-0351 2072-0378 22 1 1-143
  45. * Ostadal Petr et al. Summary of the recommendations for long-term secondary prevention after myocardial infarction. (2019) COR ET VASA 0010-8650 61 5 471-480
  46. * Valensi Paul et al. Targets for blood glucose: What have the trials told us. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_SUPPL 64-72
  47. * Standl E. et al. The global epidemics of diabetes in the 21st century: Current situation and perspectives. (2019) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 26 2_suppl 7-14
  48. Mosenzon Ofri et al. VERIFY the role of initial combination therapy in patients with type 2 diabetes. (2019) LANCET 0140-6736 1474-547X 394 10208 1483-1485
  49. Xu Yu et al. A comparative analysis of current blood pressure management guidelines in people with and without diabetes. (2020) JOURNAL OF DIABETES 1753-0393 1753-0407
  50. Koziel Monika et al. Adherence to the ABC (Atrial fibrillation Better Care) pathway in the Balkan region: the BALKAN-AF survey. (2020) POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE 0032-3772 1897-9483 130 3 187-195
  51. * Seidu S. et al. A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. (2020) PRIMARY CARE DIABETES 1751-9918
  52. Lavalle C. et al. Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. (2020) CARDIORENAL MEDICINE 1664-3828 1664-5502
  53. Fangel M.V. et al. Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. (2020) AMERICAN JOURNAL OF MEDICINE 0002-9343 1555-7162
  54. Lin Jianxiong et al. A Low Creatinine to Body Weight Ratio Predicts the Incident Nonalcoholic Fatty Liver Disease in Nonelderly Chinese without Obesity and Dyslipidemia: A Retrospective Study. (2020) GASTROENTEROLOGY RESEARCH & PRACTICE 1687-6121 1687-630X 2020
  55. Sheahan Kelsey H. et al. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. (2020) POSTGRADUATE MEDICAL JOURNAL 0032-5473 1469-0756 96 1133 156-161
  56. Kato E.T. et al. Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. (2020) TRENDS IN CARDIOVASCULAR MEDICINE 1050-1738 2020 p. Article in press
  57. * Sagar R. C. et al. Antiplatelet Therapies in Diabetes. (2020) DIABETIC MEDICINE 0742-3071 1464-5491 37 5 726-734
  58. Selby Nicholas M. et al. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 22 3-15
  59. Lüscher T.F.. A revolution in diabetes care: Novel drugs and new recommendations. (2020) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 41 2 195-198
  60. Aimo Alberto et al. Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. (2020) POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE 0032-3772 1897-9483 130 2 121-129
  61. Aimo Alberto et al. Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. (2020) ANATOLIAN JOURNAL OF CARDIOLOGY 2149-2263 2149-2271 23 2 70-78
  62. * Rocca Bianca et al. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. (2020) DIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1872-8227 160
  63. De Caterina Raffaele et al. Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review. (2020) THROMBOSIS AND HAEMOSTASIS 0340-6245 120 2 199-206
  64. Orsi Emanuela et al. Association between On-Treatment Haemoglobin A(1c) and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. (2020) JOURNAL OF CLINICAL MEDICINE 2077-0383 9 1
  65. Rafouli-Stergiou P. et al. Association of impaired arterial wall properties with the presence of coronary artery disease in patients with abdominal aortic aneurysms. (2020) JOURNAL OF CLINICAL HYPERTENSION 1524-6175 22 2 187-193
  66. Jin Jing-Lu et al. Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  67. Semb Anne Grete et al. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. (2020) NATURE REVIEWS RHEUMATOLOGY 1759-4790 1759-4804
  68. Katakami Naoto et al. Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study. (2020) DIABETES THERAPY 1869-6953 11 7 1563-1578
  69. Tarantini Luigi et al. Being a cardiologist in the days of SARS-COVID-19: is it time to reconsider the way we work?. (2020) GIORNALE ITALIANO DI CARDIOLOGIA (2006-) 1827-6806 1972-6481 21 5 E1-E2
  70. * Longato Enrico et al. Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  71. Kobalava Z.D. et al. Blood pressure phenotypes in young patients with type 1 diabetes. (2020) RUSSIAN JOURNAL OF CARDIOLOGY 1560-4071 25 3
  72. Ng Ming-Yen et al. Cardiac magnetic resonance for asymptomatic patients with type 2 diabetes and cardiovascular high risk (CATCH): a pilot study. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  73. Lehrke Michael. Cardiology update 2020. (2020) DIABETOLOGE 1860-9716 1860-9724
  74. * Sattar N. et al. Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. (2020) LANCET DIABETES & ENDOCRINOLOGY 2213-8587 2213-8595 8 5 357-360
  75. Bajaj H.S. et al. Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 22 7 1122-1131
  76. Singh A.K. et al. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. (2020) DIABETES AND METABOLIC SYNDROME: CLINICAL RESEARCH AND REVIEWS 1871-4021 14 4 715-722
  77. * Khunti Kamlesh et al. Cardiovascular outcome trials of glucose-lowering therapies. (2020) EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH 1473-7167 1744-8379 20 3 237-249
  78. Giorgino Francesco et al. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326
  79. Ruiz S. et al. Cardiovascular risk factors and cardiovascular disease in patients with type 1 diabetes and end-stage renal disease candidates for kidney-pancreas transplantation: Trends from 1999 to 2017. (2020) DIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1872-8227 163
  80. Scheen A.J.. Challenging 2019 ESC guidelines for the management of type 2 diabetes. (2020) DIABETES & METABOLISM 1262-3636 46 3 181-185
  81. Munteanu M.A. et al. Chronic heart failure and diabetes mellitus: Two unsuitably matched partners. (2020) ARCHIVES OF THE BALKAN MEDICAL UNION 1584-9244 55 1 120-133
  82. Lim Lee-Ling et al. Circulating branched-chain amino acids and incident heart failure in type 2 diabetes: The Hong Kong Diabetes Register. (2020) DIABETES-METABOLISM RESEARCH AND REVIEWS 1520-7552 1520-7560 36 3
  83. Berezin Alexander E. et al. Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review. (2020) DIABETES THERAPY 1869-6953
  84. Cai Xiao-Ling et al. Clinical evidence and treatment requirements related to heart failure in type 2 diabetes mellitus. (2020) CHINESE MEDICAL JOURNAL 0366-6999 133 10 1135-1137
  85. Lehto Hanna-Riikka et al. Clinical practice patterns in revascularization of diabetic patients with coronary heart disease: nationwide register study. (2020) ANNALS OF MEDICINE 0785-3890 52 5 225-232
  86. Wu Juan et al. Comment on Hubbard et al. Prediabetes and Risk for Cardiovascular Disease by Hypertension Status in Black Adults: The Jackson Heart Study. Diabetes Care 2019;42:2322-2329. (2020) DIABETES CARE 0149-5992 1935-5548 43 2 E32-E32
  87. Grupo de Trabajo. Comments on the 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases. (2020) REVISTA ESPANOLA DE CARDIOLOGIA 0300-8932 1579-2242 41 2
  88. * Jorsal Anders et al. Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. (2020) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 41 2 328-328
  89. * Marx Niko et al. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk. (2020) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 41 2 329-330
  90. Correale Michele et al. Comprehensive heart failure assessment: A challenge to modify the course of heart failure. Author's reply. (2020) EUROPEAN JOURNAL OF INTERNAL MEDICINE 0953-6205 1879-0828 74 125-126
  91. Ludwig Lisa et al. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials Perspective on GLP-1 RA and SGLT-2i therapies. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  92. Yu X.-Z. et al. Consensus of Chinese experts on the construction and standardization of emergency medical laboratory capability. (2020) MEDICAL JOURNAL OF CHINESE PEOPLE'S LIBERATION ARMY 0577-7402 45 1 21-42
  93. Vaduganathan Muthiah et al. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF The CHAMP-HF Registry. (2020) JACC-HEART FAILURE 2213-1779 2213-1787 8 6 469-480
  94. Kario K. et al. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. (2020) PROGRESS IN CARDIOVASCULAR DISEASES 0033-0620
  95. Kraft A. K. et al. Core aspects of a needs-conform care of patients with multiple sclerosis Utilization of outpatient services and shared decision making. (2020) NERVENARZT 0028-2804 1433-0407
  96. Soini E. et al. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. (2020) ADVANCES IN THERAPY 0741-238X
  97. Julian G.S. et al. Cost of macrovascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil. (2020) JOURNAL OF MEDICAL ECONOMICS 1369-6998
  98. Aleksova A. et al. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?. (2020) JOURNAL OF INTERNAL MEDICINE 0954-6820 1365-2796
  99. Korostovtseva L.S. et al. COVID-19: What are the risks in hypertensive patients?. (2020) ARTERIALNAYA GIPERTENZIYA 1607-419X 2411-8524 26 2 124-132
  100. Al-Bazz D.Y. et al. Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes. (2020) FUTURE CARDIOLOGY 1479-6678 1744-8298 16 2 77-88
  101. Chen Huan et al. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. (2020) CARDIOVASCULAR DRUGS AND THERAPY 0920-3206 1573-7241
  102. Persson Sofie et al. Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326
  103. Rhee J.J. et al. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 22 S1 46-54
  104. Hernandez-Baixauli Julia et al. Detection of Early Disease Risk Factors Associated with Metabolic Syndrome: A New Era with the NMR Metabolomics Assessment. (2020) NUTRIENTS 2072-6643 2072-6643 12 3
  105. * Sciatti Edoardo et al. Diabetes mellitus and chronic kidney disease: A neglected and dangerous liaison. (2020) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 In press
  106. * Schuett Katharina et al. Diabetes mellitus and heart. (2020) DIABETOLOGE 1860-9716 1860-9724 16 3 288-291
  107. Wilcox T. et al. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. (2020) JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 1558-3597 75 16 1956-1974
  108. Stompor Tomasz et al. Diagnosis and treatment of type 2 diabetes mellitus in patients with chronic kidney disease and eGFR < 60 mL/min - a position statement of the Polish Society of Nephrology Working Group on Metabolic and Endocrine Disorders in Kidney Diseases. (2020) ENDOKRYNOLOGIA POLSKA 0423-104X 71 1 3-14
  109. Leone Alessandro et al. Dietary Habits of Saharawi Type II Diabetic Women Living in Algerian Refugee Camps: Relationship with Nutritional Status and Glycemic Profile. (2020) NUTRIENTS 2072-6643 2072-6643 12 2
  110. Bernfort L. et al. Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study. (2020) DIABETES THERAPY 1869-6953
  111. Hirai Hiroyuki et al. Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial. (2020) JOURNAL OF CLINICAL MEDICINE 2077-0383 9 1
  112. * Ling Suping et al. Durability of glycaemic control in patients with type 2 diabetes after metformin failure: Prognostic model derivation and validation using the DISCOVER study. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 22 5 828-837
  113. Garcia Rodriguez Luis et al. Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. (2020) JOURNAL OF CLINICAL MEDICINE 2077-0383 9 4
  114. Johansen Nicklas J. et al. Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326
  115. Gallo Silvina et al. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. (2020) DIABETES THERAPY 1869-6953
  116. Marso Steven P. et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. (2020) JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 1558-3597 75 10 1128-1141
  117. Redouane Brahim et al. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction Insights From the FIGHT Trial. (2020) CIRCULATION-HEART FAILURE 1941-3289 1941-3297 13 5
  118. Ida Satoshi et al. Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. (2020) HEART FAILURE REVIEWS 1382-4147
  119. Li Yi Ming et al. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naive Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1. (2020) DIABETES THERAPY 1869-6953 11 5 1077-1090
  120. Del Prato Stefano et al. Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326
  121. Hu Zhipeng et al. Efficacy and safety of shenqi compound for the treatment of diabetic macroangiopathy A protocol for systematic review and meta-analysis. (2020) MEDICINE 0025-7974 1536-5964 99 15
  122. Scheen A.J.. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. (2020) EXPERT OPINION ON DRUG SAFETY 1474-0338 19 3 243-256
  123. Chudleigh Richard A. et al. Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. (2020) CURRENT MEDICAL RESEARCH AND OPINION 0300-7995 1473-4877 36 2 209-211
  124. Gulsin Gaurav S. et al. Emerging glucose-lowering therapies: a guide for cardiologists. (2020) HEART 1355-6037 106 1 18-23
  125. Giorda C.B.. European guidelines on diabetes, pre-diabetes and cardiovascular disease: What's new? The diabetologist's point of view. (2020) GIORNALE ITALIANO DI CARDIOLOGIA (2006-) 1827-6806 1972-6481 21 4 252-255
  126. * Seferović P.M. et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. (2020) EUROPEAN JOURNAL OF HEART FAILURE 1388-9842 1879-0844 22 2 196-213
  127. * Cannon Christopher P. et al. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7% Results From the CREDENCE Trial. (2020) CIRCULATION 0009-7322 1524-4539 141 5 407-410
  128. Schuett Katharina A.. Evidence-based reduction of cardiovascular risk in patients with diabetes. (2020) HERZ 0340-9937 1615-6692 45 2 118-121
  129. Pérez Cabeza A.I. et al. Expert recommendations on improving effective ischemic stroke prevention in nonvalvular atrial fibrillation: the role of rivaroxaban. (2020) REVISTA ESPANOLA DE CARDIOLOGIA SUPLEMENTOS 1131-3587 20 21-29
  130. * Bonora Benedetta Maria et al. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. (2020) DIABETES METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY 1178-7007 13 161-174
  131. Lindholt Jes Sanddal et al. Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes. (2020) CLINICAL EPIDEMIOLOGY 1179-1349 12 447-455
  132. Cheng J.W.M. et al. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease. (2020) ANNALS OF PHARMACOTHERAPY 1060-0280 1542-6270
  133. Singh Awadhesh Kumar et al. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. (2020) DIABETES AND METABOLIC SYNDROME: CLINICAL RESEARCH AND REVIEWS 1871-4021 14 3 181-187
  134. Li Jie et al. Gender difference in the association of serum selenium with all-cause and cardiovascular mortality. (2020) POSTGRADUATE MEDICINE 0032-5481 132 2 148-155
  135. Castellana Marco et al. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  136. Gonçalvesová E.. Heart failure and diabetes mellitus. Dangerous association. (2020) CARDIOLOGY LETTERS 1338-3655 1338-3760 29 1 9-16
  137. Bagriy A.E. et al. Heart failure and type 2 diabetes: Current state of the problem. (2020) RUSSIAN JOURNAL OF CARDIOLOGY 1560-4071 25 4 79-85
  138. * Ritsinger V. et al. Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. (2020) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 In press p. In press
  139. Aggarwal Y. et al. Heart rate variability features from nonlinear cardiac dynamics in identification of diabetes using artificial neural network and support vector machine. (2020) BIOCYBERNETICS AND BIOMEDICAL ENGINEERING 0208-5216 40 3 1002-1009
  140. * Hansen Dominique et al. High awareness of diabetes as a key cardiovascular risk factor among healthcare professionals but suboptimal treatment: Results from a survey of the European Association of Preventive Cardiology. (2020) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881
  141. * Lee M.M.Y. et al. How Do SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes?: Completed and ongoing mechanistic trials. (2020) ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 1079-5642 1524-4636 40 506-522
  142. Bianchi M.L. et al. Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment. (2020) OSTEOPOROSIS INTERNATIONAL 0937-941X 1433-2965
  143. Masson Walter et al. Impact of the 2019 European Guidelines on Diabetes in Clinical Practice: Real and Simulated Analyses of Lipid Goals. (2020) Journal of Cardiovascular Development and Disease, 2308-3425 7 1
  144. Huang Yu-qing et al. Impacts of Pre-Diabetes or Prehypertension on Subsequent Occurrence of Cardiovascular and All-Cause Mortality among Population without Cardiovascular Diseases. (2020) DIABETES METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY 1178-7007 13 1743-1752
  145. * Valensi P.. Importance of cardiovascular risk assessment for an individualised therapeutic strategy including the new glucose-lowering drugs in cardiovascular prevention. (2020) MEDECINE DES MALADIES METABOLIQUES 1957-2557
  146. Marre M.. Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 22 S2 33-42
  147. Koliaki C. et al. Important considerations for the treatment of patients with diabetes mellitus and heart failure from a diabetologist’s perspective: Lessons learned from cardiovascular outcome trials. (2020) INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 1661-7827 1660-4601 17 1
  148. Al-Mashat M. et al. Increased pulmonary blood volume variation in patients with heart failure compared to healthy controls: A noninvasive, quantitative measure of heart failure. (2020) JOURNAL OF APPLIED PHYSIOLOGY 8750-7587 1522-1601 128 2 324-337
  149. Funamizu Takehiro et al. Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  150. Hanefeld Markolf et al. Insulin therapy of diabetes mellitus type 2: patient-centred, timely, benefit-risk balanced; positioning 2019 after the ADA/EASD consensus in 2018. (2020) DIABETOLOGIE UND STOFFWECHSEL 1861-9002 15 1 65-75
  151. * Hassanein Mohamed et al. Introduction: Real-World Evidence in Type 2 Diabetes. (2020) DIABETES THERAPY 1869-6953
  152. Liu K.-X. et al. Investigation on the Influencing Factors of Adult Dyslipidemia in Shunqing District of Nanchong City. (2020) JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION) 1672-173X 51 1 54-59
  153. Dardano A. et al. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?. (2020) DIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1872-8227 162
  154. Jensen Rebekka Vibjerg et al. Ischemic Heart Disease: An Update. (2020) SEMINARS IN NUCLEAR MEDICINE 0001-2998 50 3 195-207
  155. Alexander C.M.. Is Heart Failure Still the Frequent, Forgotten, and Often Fatal Complication of Diabetes?. (2020) JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 1558-3597 75 11 1263-1265
  156. Targher Giovanni. Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus?. (2020) HEPATOBILIARY SURGERY AND NUTRITION 2304-3881 9 2 239-241
  157. * Ceriello Antonio et al. Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era. (2020) DIABETES CARE 0149-5992 1935-5548 43 7 1427-1432
  158. Mustroph J. et al. Kardiovaskuläre Effekte von SGLT-2-Inhibitoren. (2020) Diabetes Aktuell 1861-6089 18 3 127-131
  159. Kommentar. (2020) DIABETOLOGIE UND STOFFWECHSEL 1861-9002 15 1 32-33
  160. Alves-Cabratosa L. et al. Levels of ankle-brachial index and the risk of diabetes mellitus complications. (2020) BMJ OPEN DIABETES RESEARCH & CARE 2052-4897 8 1
  161. Brugger A.. Liraglutide (Victoza (R)) in current Guidelines Outstanding Evidence for cardiovascular Risk Reduction. (2020) JOURNAL FUR KARDIOLOGIE 1024-0098 1680-936X 27 5 190-192
  162. * Paolillo S. et al. Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction: Insights from the MECKI Score database. (2020) INTERNATIONAL JOURNAL OF CARDIOLOGY 0167-5273 1874-1754
  163. * Ceriello A.. Management of diabetes today: An exciting confusion. (2020) DIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1872-8227 162
  164. Butler Javed et al. Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 22 8 1243-1262
  165. Scheen A.J.. Management of patients with type 2 diabetes at cardiovascular renal risk: Critical analysis of the guidelines by the European Society of Cardiology. (2020) MEDECINE DES MALADIES METABOLIQUES 1957-2557
  166. Nixdorff Uwe. Meaningful diagnostics: imaging. (2020) HERZ 0340-9937 1615-6692 45 1 17-23
  167. Buitrago Sandoval A.F. et al. Mechanism of action of Type 2 Sodium-Glucose Cotransporter Inhibitors: Beyond glycaemic control. (2020) REVISTA COLOMBIANA DE CARDIOLOGÍA 2357-3260 0120-5633 27 22-25
  168. * Petrie John R. et al. Metformin and cardiorenal outcomes in diabetes: A reappraisal. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 22 6 904-915
  169. Salvatore Teresa et al. Metformin: An old drug against old age and associated morbidities. (2020) DIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1872-8227 160
  170. Mordi Ify R. et al. Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. (2020) ESC HEART FAILURE 2055-5822 7 3 1168-1177
  171. Gollmer Johannes et al. Mitochondrial Mechanisms in Diabetic Cardiomyopathy. (2020) DIABETES AND METABOLISM JOURNAL 2233-6079 2233-6087 44 1 33-53
  172. * Delgado Victoria et al. Multimodality imaging: Bird's eye view from the European Society of Cardiology Congress 2019 Paris, August 31st-September 4th, 2019. (2020) JOURNAL OF NUCLEAR CARDIOLOGY 1071-3581 1532-6551 27 1 53-61
  173. Katsiki N. et al. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. (2020) METABOLISM-CLINICAL AND EXPERIMENTAL 0026-0495 1532-8600 107
  174. * Mueller-Wieland Dirk et al. New oral antidiabetic drugs. (2020) HERZ 0340-9937 1615-6692
  175. Gwechenberger M.. News: 2019 ESC guidelines on diabetes, prediabetes and cardiovascular diseases in cooperation with the EASD. (2020) JOURNAL FUR KARDIOLOGIE 1024-0098 1680-936X 27 1-2 55-56
  176. Moertl D.. News: Heart failure: Focus on drug therapy. (2020) JOURNAL FUR KARDIOLOGIE 1024-0098 1680-936X 27 1-2 57-58
  177. Capehorn Matthew et al. Once-Weekly Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10. (2020) DIABETES THERAPY 1869-6953 11 5 1061-1075
  178. Akhtereyev R.N. et al. Outcomes in patients with hypertension and type 2 diabetes receiving a stent for angina. (2020) RUSSIAN JOURNAL OF CARDIOLOGY 1560-4071 25 4
  179. Chen Qu et al. Outcomes of type A intramural hematoma: Influence of diabetes mellitus. (2020) JOURNAL OF CARDIAC SURGERY 0886-0440 1540-8191
  180. Barrios V. et al. Patients with a high cardiovascular risk and atrial fibrillation: the role of rivaroxaban. (2020) REVISTA ESPANOLA DE CARDIOLOGIA SUPLEMENTOS 1131-3587 20 30-38
  181. Urbak L. et al. Patients with Unstable Atherosclerosis Have More Echolucent Carotid Plaques Compared with Stable Atherosclerotic Patients: A 3-D Ultrasound Study. (2020) ULTRASOUND IN MEDICINE AND BIOLOGY 0301-5629 1879-291X
  182. Scheen A.J.. Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. (2020) CLINICAL PHARMACOKINETICS 0312-5963 In press p. In press
  183. Panoulas V. et al. Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. (2020) EXPERT REVIEW OF CLINICAL PHARMACOLOGY 1751-2433 1751-2441
  184. Halimi S.. Place of the new antidiabetics in the type 2 diabetes recent Consensus: EASD/ADA and ESC 2019. Is it reasonable and feasible?. (2020) MEDECINE DES MALADIES METABOLIQUES 1957-2557 14 1 1-3
  185. Chewcharat Api et al. Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials. (2020) INTERNATIONAL UROLOGY AND NEPHROLOGY 0301-1623 1573-2584
  186. Muessig Johanna M. et al. Poor glycemic control impairs the cardioprotective effects of red blood cells on myocardial ischemia/reperfusion injury. (2020) NITRIC OXIDE-BIOLOGY AND CHEMISTRY 1089-8603 1089-8611 97 1-10
  187. Patoulias Dimitrios et al. Postdischarge antidiabetic treatment in patients with type 2 diabetes and acute coronary syndrome: time for a change?. (2020) KARDIOLOGIA POLSKA 0022-9032 1897-4279 78 5 482-483
  188. Tomlinson Brian et al. Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. (2020) EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM 1744-6651 15 3 147-157
  189. Honigberg M.C. et al. Practical considerations for the use of sodium- glucose co-transporter 2 inhibitors in heart failure. (2020) CIRCULATION-HEART FAILURE 1941-3289 1941-3297 13 2
  190. Wu J. et al. Prediabetes and risk for cardiovascular disease by hypertension status in black adults: The Jackson Heart Study. Diabetes Care 2019;42:2322-2329. (2020) DIABETES CARE 0149-5992 1935-5548 43 2 p. E32
  191. * Slater Thomas A. et al. Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice. (2020) EUROPEAN HEART JOURNAL - CARDIOVASCULAR PHARMACOTHERAPY 2055-6837 2055-6845 6 3 194-196
  192. Brath H. et al. Primary and secondary prevention in cardiovascular diseases. (2020) JOURNAL FUR KARDIOLOGIE 1024-0098 1680-936X 27 1-2 12-30
  193. Shubrook Jay H. et al. Primary Care Physicians' Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey. (2020) ADVANCES IN THERAPY 0741-238X
  194. Muehleck Franziska et al. Primary prevention of coronary heart disease Evidence-based drug treatment. (2020) HERZ 0340-9937 1615-6692 45 1 39-49
  195. Espinola-Klein Christine. Principles of angiology in lower extremity arterial disease (LEAD). (2020) HERZ 0340-9937 1615-6692 45 2 201-208
  196. * Marx N. et al. Proceedings of the Guideline Workshop 2019 – Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases. (2020) DIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1872-8227 162
  197. * Marx Nikolaus et al. Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases, and Kidney Diseases. (2020) DIABETES TECHNOLOGY AND THERAPEUTICS 1520-9156 1557-8593 22 7 546-552
  198. Zhang Hui-Wen et al. Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  199. Patoulias Dimitrios et al. Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. (2020) JOURNAL OF CLINICAL HYPERTENSION 1524-6175 22 4 562-571
  200. Tanaka A. et al. Promising roles of sodium–glucose cotransporter 2 inhibitors in heart failure prevention and treatment. (2020) DIABETOLOGY INTERNATIONAL 2190-1678 2190-1686
  201. Ghosal S. et al. Quantitative measure of asymptomatic cardiovascular disease risk in Type 2 diabetes: Evidence from Indian outpatient setting. (2020) INDIAN HEART JOURNAL 0019-4832 2213-3763
  202. Hanefeld Markolf et al. Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. (2020) DIABETES THERAPY 1869-6953
  203. Robinson S. et al. Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review. (2020) DIABETES THERAPY 1869-6953
  204. Men P. et al. Recommendations on sodium-glucose co-transporters 2 inhibitors: a review based on foreign guidelines and health technology assessment reports. (2020) Chinese Journal of Diabetes Mellitus 1674-5809 12 4 275-280
  205. Gallagher Joseph et al. Reducing Heart Failure Risk in People With Diabetes: The STOP HF Midlands Project. (2020) JOURNAL OF CARDIAC FAILURE 1071-9164 1532-8414 26 5 444-445
  206. Scheen A. J.. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. (2020) DIABETES & METABOLISM 1262-3636 46 3 186-196
  207. Rostoff Pawel et al. Relationship among the leptin-to-adiponectin ratio, systemic inflammation, and anisocytosis in well-controlled type 2 diabetic patients with atherosclerotic cardiovascular disease. (2020) KARDIOLOGIA POLSKA 0022-9032 1897-4279 78 5 420-428
  208. Weir M.R. et al. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. (2020) AMERICAN JOURNAL OF NEPHROLOGY 0250-8095 1421-9670 51 276-278
  209. * Schnell O. et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  210. Kosiborod Mikhail. RESPONSE: The Imperative to Change the Delivery of Cardiometabolic Care The Future Is Now. (2020) JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 1558-3597 75 10 1236-1237
  211. Drinkwater Jocelyn J. et al. Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  212. Cannistraci R. et al. Risk stratification tools for heart failure in the diabetes clinic. (2020) NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES 0939-4753 1590-3729
  213. * Khunti Kamlesh et al. Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. (2020) DIABETES THERAPY 1869-6953 In press p. In press
  214. * Ferrannini Giulia et al. Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. (2020) DIABETES CARE 0149-5992 1935-5548 43 4 726-733
  215. Tanaka A. et al. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial. (2020) JOURNAL OF DIABETES INVESTIGATION 2040-1116 2040-1124
  216. * Ambrosetti Marco et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. (2020) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881
  217. Romaguera Rafael et al. Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design. (2020) AMERICAN HEART JOURNAL 0002-8703 1097-6744 222 174-182
  218. Chiang Chern-En et al. Second revolution in cardiovascular prevention. (2020) JOURNAL OF THE CHINESE MEDICAL ASSOCIATION 1726-4901 83 4 327-336
  219. María Cepeda J. et al. Selecting the best anticoagulant treatment for patients with atrial fibrillation and diabetes or chronic kidney disease: the role of rivaroxaban. (2020) REVISTA ESPANOLA DE CARDIOLOGIA SUPLEMENTOS 1131-3587 20 39-45
  220. Cosin-Sales J. et al. Selection of the best of 2019 in clinical cardiology. (2020) REC: CardioClinics 2605-1532 55 51-57
  221. Husain Mansoor et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 22 3 442-451
  222. [Anonymous]. Setting therapeutic targets in diabetes. (2020) CLINICAL DIABETOLOGY 2450-7458 2450-8187 9 1 10-12
  223. Luescher Thomas F.. Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure. (2020) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 41 13 1311-1314
  224. Pareek Anil et al. SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy-evidence and implications. (2020) INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES 0973-3930
  225. Yurista Salva R. et al. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  226. Arnott C. et al. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. (2020) JOURNAL OF THE AMERICAN HEART ASSOCIATION 2047-9980 2047-9980 9 3
  227. Arow M. et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. (2020) CARDIOVASCULAR DIABETOLOGY 1475-2840 19 1
  228. Cavusoglu Yuksel et al. Sodium glucose co-transporter 2 inhibitors in heart failure therapy. (2020) TURK KARDIYOLOJI DERNEGI ARSIVI / ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY 1016-5169 1308-4488 48 3 330-354
  229. * Koufakis T. et al. Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?. (2020) JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY 1932-3107 1932-2968
  230. Brito Dulce et al. Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential. (2020) CARDIOVASCULAR DRUGS AND THERAPY 0920-3206 1573-7241 34 3 419-436
  231. Schernthaner Guntram et al. Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. (2020) DIABETES OBESITY & METABOLISM 1462-8902 1463-1326 In press p. In press
  232. Vinals C. et al. Steno type 1 risk engine and preclinical atherosclerosis in Mediterranean individuals with type 1 diabetes. (2020) DIABETES-METABOLISM RESEARCH AND REVIEWS 1520-7552 1520-7560
  233. Błaszkowska M. et al. Subclinical macroangiopathic target organ damage in type 1 diabetes mellitus patients. (2020) BLOOD PRESSURE 0803-7051 1651-1999
  234. Cho Leslie et al. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women JACC State-of-the-Art Review. (2020) JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 1558-3597 75 20 2602-2618
  235. Pop Dana et al. The control of cardiovascular risk factors - an essential component of the rehabilitation of patients with ischemic heart disease. What are the current targets?. (2020) BALNEO RESEARCH JOURNAL 2069-7597 11 1 20-23
  236. Rasmussen Mads Frederik. The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes. (2020) DIABETOLOGY INTERNATIONAL 2190-1678 2190-1686
  237. * Nedogoda S.V. et al. The effect of various classes of glucose-lowering medications on the blood vessel elasticity in patients with type 2 diabetes. (2020) RUSSIAN JOURNAL OF CARDIOLOGY 1560-4071 25 4 65-71
  238. * Manolis A. J. et al. The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind?. (2020) EUROPEAN JOURNAL OF INTERNAL MEDICINE 0953-6205 1879-0828 72 5-8
  239. Ohara Ken et al. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. (2020) DIABETOLOGY AND METABOLIC SYNDROME 1758-5996 12 1
  240. * Scherrenberg Martijn et al. The future is now: a call for action for cardiac telerehabilitation in the COVID-19 pandemic from the secondary prevention and rehabilitation section of the European Association of Preventive Cardiology. (2020) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881
  241. Yu Miao. The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy. (2020) DIABETES THERAPY 1869-6953 11 SUPPL 1 23-28
  242. * Mueller-Wieland Dirk et al. Therapy of type 2 diabetes Recommendations of the European Association for the Study of Diabetes (EASD). (2020) DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 0012-0472 1439-4413 145 9 593-600
  243. Schernthaner G. et al. The right place for metformin today. (2020) DIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1872-8227 159
  244. * Koufakis T. et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. (2020) JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS 0269-4727 2020 p. Article in press
  245. * Ray K.K. et al. The year in cardiology: Cardiovascular prevention. (2020) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 41 11 1157-1163
  246. Cheng A.Y.Y. et al. Time to Rethink Reducing Cardiovascular Risk: Are We Ready?. (2020) CANADIAN JOURNAL OF DIABETES 1499-2671 1499-2671 44 1 1-3
  247. Tan M. et al. Treating Dyslipidemias in the Primary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults with Diabetes Mellitus. (2020) CLINICS IN GERIATRIC MEDICINE 0749-0690
  248. Targher Giovanni et al. Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk. (2020) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 41 2 331-331
  249. [Anonymous]. Treatment of dyslipidemia. (2020) CLINICAL DIABETOLOGY 2450-7458 2450-8187 9 1 34-37
  250. Standl E. et al. Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. (2020) DIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1872-8227 161
  251. Katsimardou A. et al. Treatment strategies for hypertension in patients with type 1 diabetes. (2020) EXPERT OPINION ON PHARMACOTHERAPY 1465-6566 1744-7666 In press p. In press
  252. Pedro-Botet J. et al. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. (2020) CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS 0214-9168
  253. * Prattichizzo F. et al. Two drugs are better than one to start T2DM therapy. (2020) NATURE REVIEWS ENDOCRINOLOGY 1759-5029 1759-5037 16 1 15-16
  254. Scholz Gerhard Harry. Type-2 Diabetes: GLP-1 Receptor Agonists improve the cardiovascular Outcomes Comment. (2020) DIABETOLOGIE UND STOFFWECHSEL 1861-9002 15 1 32-33
  255. de Toledo Francoise et al. Unravelling the health effects of fasting: a long road from obesity treatment to healthy life span increase and improved cognition. (2020) ANNALS OF MEDICINE 0785-3890 52 5 147-161
  256. * Piepoli Massimo F. et al. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology*. (2020) EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2047-4881 27 2 181-205
  257. Davies M.J. et al. Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. (2020) METABOLISM-CLINICAL AND EXPERIMENTAL 0026-0495 1532-8600 107
  258. Custodio Jr Joaquim et al. Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects. (2020) DRUGS & AGING 1170-229X 1179-1969 In press p. In press
  259. Butler J. et al. Use of sodium–glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. (2020) EUROPEAN JOURNAL OF HEART FAILURE 1388-9842 1879-0844 22 4 604-617
  260. Vinci M.C. et al. When good guys turn bad: Bone Marrow’s and hematopoietic stem cells’ role in the pathobiology of diabetic complications. (2020) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 21 11 1-22
  261. Bloomgarden Zachary T.. Which person with diabetes should receive cardioprotective glucose-lowering medicines?. (2020) JOURNAL OF DIABETES 1753-0393 1753-0407 12 5 352-353
2020-08-03 23:30